LisenID is advancing cancer healthcare using epigenetic imprinting solutions and AI. Our patent pending technology (Quantitative Chromogenic Imprinted Gene In-Situ Hybridization, QCIGISH) accurately detects 12 types of cancers via minimally invasive biopsy and liquid collection kits. The methodology has already been validated through 7000+ clinical cases in partnership with 20+ hospitals. Our solution offers market leading sensitivity and specificity, which equip healthcare providers with the means to best treat patients earlier and throughout their treatment lifecycle.